carnitine has been researched along with Cancer of Liver in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Longitudinal assessments of carnitine and fatigue in patients with hepatocellular carcinoma suggest that lenvatinib affects the carnitine system in patients undergoing lenvatinib therapy and that carnitine insufficiency increases fatigue." | 9.34 | Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma. ( Ando, H; Ikejima, K; Ishizuka, K; Kitagawa, R; Kokubu, S; Miyazaki, A; Nagahara, A; Okubo, H; Okubo, S; Saito, H; Shiina, S, 2020) |
| " Therefore, this study aimed to evaluate the effects of lenvatinib (LEN) on skeletal muscle volume and cardiac function in patients with hepatocellular carcinoma (HCC)." | 8.31 | Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma. ( Amanuma, M; Daido, Y; Higai, K; Igarashi, Y; Kobayashi, K; Matsuda, T; Matsui, T; Matsukiyo, Y; Mohri, K; Momiyama, K; Mukozu, T; Nagai, H; Nagumo, H; Ogino, Y; Wakui, N; Watanabe, G; Yoshimine, N, 2023) |
| "Carnitine metabolism is thought to be negatively correlated with the progression of hepatocellular carcinoma (HCC) and the specific molecular mechanism is yet to be fully elucidated." | 8.12 | CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma. ( Chen, K; Lin, W; Liu, C; Lu, Y; Wang, H; Wang, J; Zhang, D; Zhang, Y; Zhao, L; Zhao, W; Zhou, Y, 2022) |
| "This study investigated the inhibitory effect of levocarnitine supplementation on sarcopenia progression in hepatocellular carcinoma (HCC) patients treated with lenvatinib." | 8.02 | Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis. ( Ando, H; Ikejima, K; Nagahara, A; Nakadera, E; Okubo, H; Shiina, S, 2021) |
| " In this study, we measured the serum levels of 15 acylcarnitine species of various carbon chain lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatocellular carcinoma (HCC), and analyzed the relationship between serum acylcarnitine profile and NAFLD status." | 7.91 | Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. ( Enooku, K; Fujiwara, N; Hoshida, Y; Koike, K; Kondo, M; Minami, T; Nakagawa, H; Shibahara, J; Tateishi, R, 2019) |
| " L-Carnitine is a vitamin-like substance and several reports have described the usefulness of L-carnitine supplementation in cases of cirrhosis, with confirmed effectiveness against refractory hepatic encephalopathy." | 7.81 | Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma. ( Hasegawa, H; Ishihara, T; Iwasa, M; Kobayashi, Y; Mifuji-Moroka, R; Sekoguchi-Fujikawa, N; Sugimoto, R; Takei, Y; Tanaka, H; Yoshikawa, K, 2015) |
| "Persistent antigen exposure during chronic hepatitis B infection leads to exhausted immune responses, thus impeding viral control." | 5.62 | High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. ( Chen, C; Chen, H; Fu, X; Gu, S; Hou, J; Jiang, D; Li, X; Li, Y; Tang, L; Ye, G; Zhong, S, 2021) |
| "Longitudinal assessments of carnitine and fatigue in patients with hepatocellular carcinoma suggest that lenvatinib affects the carnitine system in patients undergoing lenvatinib therapy and that carnitine insufficiency increases fatigue." | 5.34 | Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma. ( Ando, H; Ikejima, K; Ishizuka, K; Kitagawa, R; Kokubu, S; Miyazaki, A; Nagahara, A; Okubo, H; Okubo, S; Saito, H; Shiina, S, 2020) |
| " Therefore, this study aimed to evaluate the effects of lenvatinib (LEN) on skeletal muscle volume and cardiac function in patients with hepatocellular carcinoma (HCC)." | 4.31 | Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma. ( Amanuma, M; Daido, Y; Higai, K; Igarashi, Y; Kobayashi, K; Matsuda, T; Matsui, T; Matsukiyo, Y; Mohri, K; Momiyama, K; Mukozu, T; Nagai, H; Nagumo, H; Ogino, Y; Wakui, N; Watanabe, G; Yoshimine, N, 2023) |
| "Carnitine metabolism is thought to be negatively correlated with the progression of hepatocellular carcinoma (HCC) and the specific molecular mechanism is yet to be fully elucidated." | 4.12 | CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma. ( Chen, K; Lin, W; Liu, C; Lu, Y; Wang, H; Wang, J; Zhang, D; Zhang, Y; Zhao, L; Zhao, W; Zhou, Y, 2022) |
| "This study investigated the inhibitory effect of levocarnitine supplementation on sarcopenia progression in hepatocellular carcinoma (HCC) patients treated with lenvatinib." | 4.02 | Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis. ( Ando, H; Ikejima, K; Nagahara, A; Nakadera, E; Okubo, H; Shiina, S, 2021) |
| " In this study, we measured the serum levels of 15 acylcarnitine species of various carbon chain lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatocellular carcinoma (HCC), and analyzed the relationship between serum acylcarnitine profile and NAFLD status." | 3.91 | Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. ( Enooku, K; Fujiwara, N; Hoshida, Y; Koike, K; Kondo, M; Minami, T; Nakagawa, H; Shibahara, J; Tateishi, R, 2019) |
| " L-Carnitine is a vitamin-like substance and several reports have described the usefulness of L-carnitine supplementation in cases of cirrhosis, with confirmed effectiveness against refractory hepatic encephalopathy." | 3.81 | Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma. ( Hasegawa, H; Ishihara, T; Iwasa, M; Kobayashi, Y; Mifuji-Moroka, R; Sekoguchi-Fujikawa, N; Sugimoto, R; Takei, Y; Tanaka, H; Yoshikawa, K, 2015) |
| "It can be concluded that L-carnitine supplementation may be a good approach for a multi-targeted therapy for the treatment of cancer-related cachexia." | 3.78 | L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. ( Argilés, JM; Betancourt, A; Busquets, S; Capdevila, E; López-Soriano, FJ; Macciò, A; Madeddu, C; Mantovani, G; Marmonti, E; Orpí, M; Pin, F; Serpe, R; Toledo, M, 2012) |
| "Methods." | 2.80 | Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients. ( Abdelaal, UM; Arafa, UA; Asai, A; Fukunishi, S; Hassan, A; Hassan, AT; Higuchi, K; Kassem, AM; Nakamura, K; Ohama, H; Sujishi, T; Tsuchimoto, Y; Tsuda, Y; Yokohama, K, 2015) |
| "Persistent antigen exposure during chronic hepatitis B infection leads to exhausted immune responses, thus impeding viral control." | 1.62 | High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. ( Chen, C; Chen, H; Fu, X; Gu, S; Hou, J; Jiang, D; Li, X; Li, Y; Tang, L; Ye, G; Zhong, S, 2021) |
| "Correct staging of hepatocellular carcinoma (HCC) could help physicians to precisely select treatments for patients, such as surgery, chemotherapy, or their combination." | 1.48 | Dysregulated serum metabolites in staging of hepatocellular carcinoma. ( Chen, N; Chen, Y; Lou, B; Lv, J; Mao, W; Wang, P; Wang, W, 2018) |
| "Hepatocellular carcinoma has a poor prognosis due to its rapid development and early metastasis." | 1.39 | Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. ( Gao, P; Huang, Q; Lu, X; Tan, Y; Wang, H; Xu, G; Ye, G; Yin, P, 2013) |
| " Therefore, we investigated whether long-term administration of L-carnitine could prevent hepatitis and subsequent hepatocellular carcinoma in Long-Evans Cinnamon rats that are often analyzed as a model of hepatocarcinogenesis." | 1.33 | L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. ( Chang, B; Inoue, M; Nishiguchi, S; Nishikawa, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 4 (14.29) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 10 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Okubo, H | 2 |
| Ando, H | 2 |
| Nakadera, E | 1 |
| Ikejima, K | 2 |
| Shiina, S | 2 |
| Nagahara, A | 2 |
| Wang, J | 1 |
| Zhou, Y | 1 |
| Zhang, D | 1 |
| Zhao, W | 1 |
| Lu, Y | 1 |
| Liu, C | 1 |
| Lin, W | 1 |
| Zhang, Y | 4 |
| Chen, K | 1 |
| Wang, H | 2 |
| Zhao, L | 1 |
| Sun, J | 3 |
| Ding, J | 3 |
| Shen, Q | 3 |
| Wang, X | 3 |
| Wang, M | 3 |
| Huang, Y | 3 |
| Zhang, X | 5 |
| Zhu, H | 3 |
| Zhang, F | 4 |
| Wu, D | 3 |
| Peng, M | 3 |
| Zhang, Z | 5 |
| Yuan, Y | 3 |
| Li, W | 3 |
| She, ZG | 3 |
| Zhang, XJ | 3 |
| Li, H | 3 |
| Zhang, P | 4 |
| Huang, Z | 4 |
| Cheng, X | 3 |
| Tan, X | 2 |
| Wang, W | 5 |
| Zhu, R | 2 |
| Wu, M | 2 |
| Li, M | 3 |
| Chen, Y | 4 |
| Liang, Z | 2 |
| Zhu, P | 3 |
| Wu, X | 2 |
| Weng, X | 2 |
| Qutob, HMH | 1 |
| Saad, RA | 1 |
| Bali, H | 1 |
| Osailan, A | 1 |
| Jaber, J | 1 |
| Alzahrani, E | 1 |
| Alyami, J | 1 |
| Elsayed, H | 1 |
| Alserihi, R | 1 |
| Shaikhomar, OA | 1 |
| Divya, KM | 1 |
| Savitha, DP | 1 |
| Krishna, GA | 1 |
| Dhanya, TM | 1 |
| Mohanan, PV | 1 |
| Shah, SF | 1 |
| Jafry, AT | 1 |
| Hussain, G | 1 |
| Kazim, AH | 1 |
| Ali, M | 1 |
| Rivani, E | 1 |
| Endraswari, PD | 1 |
| Widodo, ADW | 1 |
| Khalil, MR | 1 |
| Guldberg, R | 1 |
| Nørgård, BM | 1 |
| Uldbjerg, N | 1 |
| Wehberg, S | 1 |
| Fowobaje, KR | 1 |
| Mashood, LO | 1 |
| Ekholuenetale, M | 1 |
| Ibidoja, OJ | 1 |
| Romagnoli, A | 1 |
| D'Agostino, M | 1 |
| Pavoni, E | 1 |
| Ardiccioni, C | 1 |
| Motta, S | 1 |
| Crippa, P | 1 |
| Biagetti, G | 1 |
| Notarstefano, V | 1 |
| Rexha, J | 1 |
| Perta, N | 1 |
| Barocci, S | 1 |
| Costabile, BK | 1 |
| Colasurdo, G | 1 |
| Caucci, S | 1 |
| Mencarelli, D | 1 |
| Turchetti, C | 1 |
| Farina, M | 1 |
| Pierantoni, L | 1 |
| La Teana, A | 1 |
| Al Hadi, R | 1 |
| Cicconardi, F | 1 |
| Chinappi, M | 1 |
| Trucchi, E | 1 |
| Mancia, F | 1 |
| Menzo, S | 1 |
| Morozzo Della Rocca, B | 1 |
| D'Annessa, I | 1 |
| Di Marino, D | 1 |
| Choya, A | 1 |
| de Rivas, B | 1 |
| Gutiérrez-Ortiz, JI | 1 |
| López-Fonseca, R | 1 |
| Xu, S | 1 |
| Cheng, B | 1 |
| Liu, T | 1 |
| Li, Y | 5 |
| Jiang, L | 1 |
| Guo, W | 1 |
| Xiong, J | 1 |
| Amirazodi, M | 1 |
| Daryanoosh, F | 1 |
| Mehrabi, A | 1 |
| Gaeini, A | 1 |
| Koushkie Jahromi, M | 1 |
| Salesi, M | 1 |
| Zarifkar, AH | 1 |
| Studeny, P | 1 |
| Netukova, M | 1 |
| Nemcokova, M | 1 |
| Klimesova, YM | 1 |
| Krizova, D | 1 |
| Kang, H | 1 |
| Tao, Y | 1 |
| Zhang, Q | 1 |
| Sha, D | 1 |
| Yao, J | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Ji, L | 1 |
| Shi, P | 1 |
| Shi, C | 1 |
| Wu, YL | 1 |
| Wright, AI | 1 |
| M El-Metwaly, N | 1 |
| A Katouah, H | 1 |
| El-Desouky, MG | 1 |
| El-Bindary, AA | 1 |
| El-Bindary, MA | 1 |
| Kostakis, ID | 1 |
| Raptis, DA | 1 |
| Davidson, BR | 1 |
| Iype, S | 1 |
| Nasralla, D | 1 |
| Imber, C | 1 |
| Sharma, D | 1 |
| Pissanou, T | 1 |
| Pollok, JM | 1 |
| Hughes, AM | 1 |
| Sanderson, E | 1 |
| Morris, T | 1 |
| Ayorech, Z | 1 |
| Tesli, M | 1 |
| Ask, H | 1 |
| Reichborn-Kjennerud, T | 1 |
| Andreassen, OA | 1 |
| Magnus, P | 1 |
| Helgeland, Ø | 1 |
| Johansson, S | 1 |
| Njølstad, P | 1 |
| Davey Smith, G | 1 |
| Havdahl, A | 1 |
| Howe, LD | 1 |
| Davies, NM | 1 |
| Amrillah, T | 1 |
| Prasetio, A | 1 |
| Supandi, AR | 1 |
| Sidiq, DH | 1 |
| Putra, FS | 1 |
| Nugroho, MA | 1 |
| Salsabilla, Z | 1 |
| Azmi, R | 1 |
| Grammatikopoulos, P | 1 |
| Bouloumis, T | 1 |
| Steinhauer, S | 1 |
| Mironov, VS | 2 |
| Bazhenova, TA | 2 |
| Manakin, YV | 2 |
| Yagubskii, EB | 2 |
| Yakushev, IA | 1 |
| Gilmutdinov, IF | 1 |
| Simonov, SV | 1 |
| Lan, K | 1 |
| Yang, H | 1 |
| Zheng, J | 1 |
| Hu, H | 1 |
| Zhu, T | 1 |
| Zou, X | 1 |
| Hu, B | 1 |
| Liu, H | 1 |
| Olokede, O | 1 |
| Wu, H | 1 |
| Holtzapple, M | 1 |
| Gungor, O | 1 |
| Kose, M | 1 |
| Ghaemi, R | 1 |
| Acker, M | 1 |
| Stosic, A | 1 |
| Jacobs, R | 1 |
| Selvaganapathy, PR | 1 |
| Ludwig, N | 1 |
| Yerneni, SS | 1 |
| Azambuja, JH | 1 |
| Pietrowska, M | 1 |
| Widłak, P | 1 |
| Hinck, CS | 1 |
| Głuszko, A | 1 |
| Szczepański, MJ | 1 |
| Kärmer, T | 1 |
| Kallinger, I | 1 |
| Schulz, D | 1 |
| Bauer, RJ | 1 |
| Spanier, G | 1 |
| Spoerl, S | 1 |
| Meier, JK | 1 |
| Ettl, T | 1 |
| Razzo, BM | 1 |
| Reichert, TE | 1 |
| Hinck, AP | 1 |
| Whiteside, TL | 1 |
| Wei, ZL | 1 |
| Juan, W | 1 |
| Tong, D | 1 |
| Juan, LX | 1 |
| Sa, LY | 1 |
| Jie, HFM | 1 |
| Xiao, G | 1 |
| Xiang, LG | 1 |
| Jie, HM | 1 |
| Xu, C | 1 |
| Yu, DN | 1 |
| Yao, ZX | 1 |
| Bigdeli, F | 1 |
| Gao, XM | 1 |
| Li, JZ | 1 |
| Zhang, JW | 1 |
| Guan, ZJ | 1 |
| Bu, Y | 1 |
| Liu, KG | 1 |
| Morsali, A | 1 |
| Das, R | 1 |
| Paul, R | 1 |
| Parui, A | 1 |
| Shrotri, A | 1 |
| Atzori, C | 1 |
| Lomachenko, KA | 1 |
| Singh, AK | 1 |
| Mondal, J | 1 |
| Peter, SC | 1 |
| Florimbio, AR | 1 |
| Coughlin, LN | 1 |
| Bauermeister, JA | 1 |
| Young, SD | 1 |
| Zimmerman, MA | 1 |
| Walton, MA | 1 |
| Bonar, EE | 1 |
| Demir, D | 1 |
| Balci, AB | 1 |
| Kahraman, N | 1 |
| Sunbul, SA | 1 |
| Gucu, A | 1 |
| Seker, IB | 1 |
| Badem, S | 1 |
| Yuksel, A | 1 |
| Ozyazicioglu, AF | 1 |
| Goncu, MT | 1 |
| Zhang, H | 2 |
| Zhou, H | 1 |
| Deng, Z | 1 |
| Luo, L | 1 |
| Ong, SP | 1 |
| Wang, C | 1 |
| Xin, H | 1 |
| Whittingham, MS | 1 |
| Zhou, G | 1 |
| Maemura, R | 1 |
| Wakamatsu, M | 1 |
| Matsumoto, K | 1 |
| Sakaguchi, H | 1 |
| Yoshida, N | 1 |
| Hama, A | 1 |
| Yoshida, T | 1 |
| Miwata, S | 1 |
| Kitazawa, H | 1 |
| Narita, K | 1 |
| Kataoka, S | 1 |
| Ichikawa, D | 1 |
| Hamada, M | 1 |
| Taniguchi, R | 1 |
| Suzuki, K | 1 |
| Kawashima, N | 1 |
| Nishikawa, E | 1 |
| Narita, A | 1 |
| Okuno, Y | 1 |
| Nishio, N | 1 |
| Kato, K | 1 |
| Kojima, S | 1 |
| Morita, K | 1 |
| Muramatsu, H | 1 |
| Takahashi, Y | 1 |
| Yirgu, A | 1 |
| Mekonnen, Y | 1 |
| Eyado, A | 1 |
| Staropoli, A | 1 |
| Vinale, F | 1 |
| Zac, J | 1 |
| Zac, S | 1 |
| Pérez-Padilla, R | 1 |
| Remigio-Luna, A | 1 |
| Guzmán-Boulloud, N | 1 |
| Gochicoa-Rangel, L | 1 |
| Guzmán-Valderrábano, C | 1 |
| Thirión-Romero, I | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Barantsevich, ER | 1 |
| Karakulova, YV | 1 |
| Baranova, NS | 1 |
| Morzhukhina, MV | 1 |
| Wang, Q | 3 |
| Gu, Y | 1 |
| Chen, C | 2 |
| Qiao, L | 1 |
| Pan, F | 1 |
| Song, C | 1 |
| Canetto, SS | 1 |
| Entilli, L | 1 |
| Cerbo, I | 1 |
| Cipolletta, S | 1 |
| Wu, Y | 2 |
| Jiang, Y | 1 |
| Wang, Z | 1 |
| Xie, B | 1 |
| Song, T | 1 |
| Luo, A | 1 |
| Li, S | 1 |
| Xiong, X | 1 |
| Han, J | 1 |
| Peng, X | 1 |
| Huang, L | 1 |
| Chen, Q | 1 |
| Fang, W | 1 |
| Hou, Y | 1 |
| Zhu, Y | 1 |
| Ye, J | 1 |
| Liu, L | 1 |
| Islam, MR | 1 |
| Sanderson, P | 1 |
| Johansen, MP | 1 |
| Payne, TE | 1 |
| Naidu, R | 1 |
| Cao, J | 1 |
| Yang, J | 1 |
| Niu, X | 1 |
| Liu, X | 1 |
| Zhai, Y | 1 |
| Qiang, C | 1 |
| Niu, Y | 1 |
| Li, Z | 1 |
| Dong, N | 1 |
| Wen, B | 1 |
| Ouyang, Z | 1 |
| Li, J | 2 |
| Zhao, M | 1 |
| Zhao, J | 2 |
| Morici, P | 1 |
| Rizzato, C | 1 |
| Ghelardi, E | 1 |
| Rossolini, GM | 1 |
| Lupetti, A | 1 |
| Gözüküçük, R | 1 |
| Cakiroglu, B | 1 |
| He, X | 2 |
| Li, R | 1 |
| Zhao, D | 1 |
| Zhang, L | 1 |
| Ji, X | 1 |
| Fan, X | 1 |
| Chen, J | 1 |
| Wang, Y | 3 |
| Luo, Y | 1 |
| Zheng, D | 1 |
| Xie, L | 1 |
| Sun, S | 1 |
| Cai, Z | 1 |
| Liu, Q | 1 |
| Ma, K | 1 |
| Sun, X | 1 |
| Drinkwater, JJ | 1 |
| Davis, TME | 1 |
| Turner, AW | 1 |
| Davis, WA | 1 |
| Suzuki, Y | 1 |
| Mizuta, Y | 1 |
| Mikagi, A | 1 |
| Misawa-Suzuki, T | 1 |
| Tsuchido, Y | 1 |
| Sugaya, T | 1 |
| Hashimoto, T | 1 |
| Ema, K | 1 |
| Hayashita, T | 1 |
| Yang, T | 1 |
| Liang, N | 1 |
| Zhang, J | 1 |
| Bai, Y | 2 |
| Zhao, Z | 1 |
| Chen, L | 1 |
| Yang, M | 1 |
| Huang, Q | 2 |
| Hu, P | 1 |
| Nagai, H | 1 |
| Amanuma, M | 1 |
| Mukozu, T | 1 |
| Kobayashi, K | 1 |
| Nagumo, H | 1 |
| Mohri, K | 1 |
| Watanabe, G | 1 |
| Yoshimine, N | 1 |
| Ogino, Y | 1 |
| Daido, Y | 1 |
| Matsukiyo, Y | 1 |
| Matsui, T | 1 |
| Wakui, N | 1 |
| Momiyama, K | 1 |
| Higai, K | 1 |
| Matsuda, T | 1 |
| Igarashi, Y | 1 |
| Ishizuka, K | 1 |
| Kitagawa, R | 1 |
| Okubo, S | 1 |
| Saito, H | 1 |
| Kokubu, S | 1 |
| Miyazaki, A | 1 |
| Gu, S | 1 |
| Fu, X | 1 |
| Ye, G | 2 |
| Li, X | 1 |
| Zhong, S | 1 |
| Tang, L | 1 |
| Chen, H | 1 |
| Jiang, D | 1 |
| Hou, J | 1 |
| Carayol, M | 1 |
| Leitzmann, MF | 1 |
| Ferrari, P | 1 |
| Zamora-Ros, R | 1 |
| Achaintre, D | 1 |
| Stepien, M | 1 |
| Schmidt, JA | 1 |
| Travis, RC | 1 |
| Overvad, K | 1 |
| Tjønneland, A | 1 |
| Hansen, L | 1 |
| Kaaks, R | 1 |
| Kühn, T | 1 |
| Boeing, H | 1 |
| Bachlechner, U | 1 |
| Trichopoulou, A | 1 |
| Bamia, C | 1 |
| Palli, D | 1 |
| Agnoli, C | 1 |
| Tumino, R | 1 |
| Vineis, P | 1 |
| Panico, S | 1 |
| Quirós, JR | 1 |
| Sánchez-Cantalejo, E | 1 |
| Huerta, JM | 1 |
| Ardanaz, E | 1 |
| Arriola, L | 1 |
| Agudo, A | 1 |
| Nilsson, J | 1 |
| Melander, O | 1 |
| Bueno-de-Mesquita, B | 1 |
| Peeters, PH | 1 |
| Wareham, N | 1 |
| Khaw, KT | 1 |
| Jenab, M | 1 |
| Key, TJ | 1 |
| Scalbert, A | 1 |
| Rinaldi, S | 1 |
| Fujiwara, N | 2 |
| Nakagawa, H | 2 |
| Enooku, K | 2 |
| Kudo, Y | 1 |
| Hayata, Y | 1 |
| Nakatsuka, T | 1 |
| Tanaka, Y | 1 |
| Tateishi, R | 2 |
| Hikiba, Y | 1 |
| Misumi, K | 1 |
| Tanaka, M | 1 |
| Hayashi, A | 1 |
| Shibahara, J | 2 |
| Fukayama, M | 1 |
| Arita, J | 1 |
| Hasegawa, K | 1 |
| Hirschfield, H | 1 |
| Hoshida, Y | 2 |
| Hirata, Y | 1 |
| Otsuka, M | 1 |
| Tateishi, K | 1 |
| Koike, K | 2 |
| Lv, J | 1 |
| Chen, N | 1 |
| Lou, B | 1 |
| Mao, W | 1 |
| Wang, P | 1 |
| Lu, X | 3 |
| Zhang, K | 1 |
| Zhan, C | 1 |
| Shi, X | 2 |
| Nie, H | 1 |
| Busquets, S | 2 |
| Pérez-Peiró, M | 1 |
| Salazar-Degracia, A | 1 |
| Argilés, JM | 2 |
| Serpe, R | 2 |
| Rojano-Toimil, A | 1 |
| López-Soriano, FJ | 2 |
| Barreiro, E | 1 |
| Kondo, M | 1 |
| Minami, T | 1 |
| Tan, Y | 1 |
| Yin, P | 2 |
| Gao, P | 2 |
| Xu, G | 3 |
| Nishikawa, H | 1 |
| Osaki, Y | 1 |
| Hassan, A | 1 |
| Tsuda, Y | 1 |
| Asai, A | 1 |
| Yokohama, K | 1 |
| Nakamura, K | 1 |
| Sujishi, T | 1 |
| Ohama, H | 1 |
| Tsuchimoto, Y | 1 |
| Fukunishi, S | 1 |
| Abdelaal, UM | 1 |
| Arafa, UA | 1 |
| Hassan, AT | 1 |
| Kassem, AM | 1 |
| Higuchi, K | 1 |
| Yaligar, J | 1 |
| Teoh, WW | 1 |
| Othman, R | 1 |
| Verma, SK | 1 |
| Phang, BH | 1 |
| Lee, SS | 1 |
| Wang, WW | 1 |
| Toh, HC | 1 |
| Gopalan, V | 1 |
| Sabapathy, K | 1 |
| Velan, SS | 1 |
| Iwasa, M | 1 |
| Sugimoto, R | 1 |
| Ishihara, T | 1 |
| Sekoguchi-Fujikawa, N | 1 |
| Yoshikawa, K | 1 |
| Mifuji-Moroka, R | 1 |
| Tanaka, H | 1 |
| Kobayashi, Y | 1 |
| Hasegawa, H | 1 |
| Takei, Y | 1 |
| Elsemman, IE | 1 |
| Mardinoglu, A | 1 |
| Shoaie, S | 1 |
| Soliman, TH | 1 |
| Nielsen, J | 1 |
| Al-Rejaie, SS | 1 |
| Aleisa, AM | 1 |
| Al-Yahya, AA | 1 |
| Bakheet, SA | 1 |
| Alsheikh, A | 1 |
| Fatani, AG | 1 |
| Al-Shabanah, OA | 1 |
| Sayed-Ahmed, MM | 1 |
| Zhou, L | 1 |
| Xing, W | 1 |
| Wu, Z | 1 |
| Chen, S | 1 |
| Lin, X | 1 |
| Toledo, M | 1 |
| Betancourt, A | 1 |
| Marmonti, E | 1 |
| Orpí, M | 1 |
| Pin, F | 1 |
| Capdevila, E | 1 |
| Madeddu, C | 1 |
| Mantovani, G | 1 |
| Macciò, A | 1 |
| Chang, B | 1 |
| Nishikawa, M | 1 |
| Nishiguchi, S | 1 |
| Inoue, M | 1 |
| Wang, T | 1 |
| Wan, D | 1 |
| Yang, S | 1 |
| Gu, J | 1 |
| Benvenga, S | 1 |
| Lakshmanan, M | 1 |
| Trimarchi, F | 1 |
| Watkins, PA | 1 |
| Ferrell, EV | 1 |
| Pedersen, JI | 1 |
| Hoefler, G | 1 |
2 reviews available for carnitine and Cancer of Liver
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis.
Topics: Carcinoma, Hepatocellular; Carnitine; Electric Impedance; Fibrosis; Hand Strength; Hepatitis C, Chro | 2015 |
3 trials available for carnitine and Cancer of Liver
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cardiomyopathies; Carnitine; Dietary Supplements | 2020 |
Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients.
Topics: Administration, Oral; Aged; Amino Acids, Branched-Chain; Bilirubin; Carcinoma, Hepatocellular; Carni | 2015 |
24 other studies available for carnitine and Cancer of Liver
| Article | Year |
|---|---|
Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Carnitine; Dietary Supplements; Female; Humans; | 2021 |
CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma.
Topics: beta Catenin; Carcinoma, Hepatocellular; Carnitine; Carrier Proteins; Cell Line, Tumor; Cell Prolife | 2022 |
Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Carnitine; Citrate (si)-Synthase; Humans; Liver Neoplasms; Mice | 2023 |
Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Carnitine; Citrate (si)-Synthase; Humans; Liver Neoplasms; Mice | 2023 |
Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Carnitine; Citrate (si)-Synthase; Humans; Liver Neoplasms; Mice | 2023 |
Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Carnitine; Citrate (si)-Synthase; Humans; Liver Neoplasms; Mice | 2023 |
Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma.
Topics: Antigens, CD1d; Carcinoma, Hepatocellular; Carnitine; Cellular Senescence; Galactosylceramides; Huma | 2023 |
Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma.
Topics: Antigens, CD1d; Carcinoma, Hepatocellular; Carnitine; Cellular Senescence; Galactosylceramides; Huma | 2023 |
Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma.
Topics: Antigens, CD1d; Carcinoma, Hepatocellular; Carnitine; Cellular Senescence; Galactosylceramides; Huma | 2023 |
Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma.
Topics: Antigens, CD1d; Carcinoma, Hepatocellular; Carnitine; Cellular Senescence; Galactosylceramides; Huma | 2023 |
OCTN2 enhances PGC-1α-mediated fatty acid oxidation and OXPHOS to support stemness in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Carnitine; Cell Line, Tumor; Disease Models, Animal; Fatty Acids | 2023 |
Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Carnitine; Humans; Liver Neoplasms; Muscle, Skeletal; Myostatin; P | 2023 |
High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Carnitine; Carnitine O-Palmitoyltransferase; CD4 | 2021 |
Blood Metabolic Signatures of Body Mass Index: A Targeted Metabolomics Study in the EPIC Cohort.
Topics: Adult; Amino Acids; Bile Duct Neoplasms; Biogenic Amines; Blood Proteins; Body Mass Index; Carcinoma | 2017 |
CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
Topics: Adult; Aged; Animals; Carcinoma, Hepatocellular; Carnitine; Carnitine O-Palmitoyltransferase; Case-C | 2018 |
Dysregulated serum metabolites in staging of hepatocellular carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carnitine; China; Cohort Studies; Docosah | 2018 |
Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2.
Topics: Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carnitine; Carnitine O-Palmitoyltransferase | 2019 |
Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats.
Topics: Animals; Autophagy; Cachexia; Carcinoma, Hepatocellular; Carnitine; Carnitine O-Palmitoyltransferase | 2020 |
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma.
Topics: Adult; Age Factors; Aged; Carcinoma, Hepatocellular; Carnitine; Disease Progression; Female; Humans; | 2019 |
Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
Topics: Adult; Aged; Antioxidants; Betaine; Carcinoma, Hepatocellular; Carnitine; Citric Acid Cycle; Fatty A | 2013 |
Longitudinal metabolic imaging of hepatocellular carcinoma in transgenic mouse models identifies acylcarnitine as a potential biomarker for early detection.
Topics: Animals; Biomarkers; Carcinoma, Hepatocellular; Carnitine; Diffusion Magnetic Resonance Imaging; Dis | 2016 |
Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma.
Topics: Ablation Techniques; Aged; Aged, 80 and over; Albumins; Amino Acids, Branched-Chain; Ammonia; Carcin | 2015 |
Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism.
Topics: Acyl Coenzyme A; Acyltransferases; Carcinoma, Hepatocellular; Carnitine; Chromosomes, Human, Pair 1; | 2016 |
Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Bilirubin; Carnitine; Catalase; Dietary Supplem | 2009 |
Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases.
Topics: Carcinoma, Hepatocellular; Carnitine; Chromatography, Liquid; Chronic Disease; Fatty Acids; Humans; | 2012 |
L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer.
Topics: Animals; Cachexia; Carcinoma, Hepatocellular; Carnitine; Caspase 3; Dietary Supplements; Liver Neopl | 2012 |
L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Carnitine; Copper; Fatty Acids, Nonesterified; Glutat | 2005 |
Analysis of acetylcholine, choline and butyrobetaine in human liver tissues by hydrophilic interaction liquid chromatography-tandem mass spectrometry.
Topics: Acetylcholine; Betaine; Carcinoma, Hepatocellular; Carnitine; Choline; Chromatography, Liquid; Human | 2008 |
Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake.
Topics: Animals; Biological Transport; Carbon Radioisotopes; Carcinoma, Hepatocellular; Carnitine; Cell Line | 2000 |
Peroxisomal fatty acid beta-oxidation in HepG2 cells.
Topics: Acyl-CoA Oxidase; Antimycin A; Carcinoma, Hepatocellular; Carnitine; Cell Line; Coenzyme A Ligases; | 1991 |